


Group Managing Director Report Kate Quirke

Group Managing Director | CEO



Market outlook

Hospitals are increasingly seeking seamless, digital solutions to manage clinical workflow



Need for improved healthcare workflow and digital solutions heighted as result of COVID




Digital strategy provides potential to disrupt large EPR vendors


NHS + digital health market changing in UK, leading to growing adoption of larger integrated EPR contracts

- Concept of an EPR is maturing in the UK; market moving from standalone PAS to an integrated EPR given increasing demand for clinical capabilities
 – A core competency of Alcidion!
- EPR wins by major global vendors from larger hospitals has increased over recent years
- However, the adoption of 'Tier 2' vendors from mid/smaller hospitals has been slower driven by perception of higher impact (software only without support) & cost (minimal cost differential) leading buyers to large EPRs

Digital Strategy & Alcidion Opportunity

- As Trusts look for integrated EPRs, there is demand & market opportunity for new players with an open platform, modern & modular architecture, mobility & improved price point
- Using Miya Precision as the **core orchestration layer**, Alcidion can layer their own solutions (partnering with others (Better Meds) as required) to create a modular ecosystem EPR that is agnostic of the care setting







Alcidion's flow solution: Miya Flow

Foundation module of Miya Precision, Miya Flow addresses these challenges by

- Providing clinicians with insight to all factors relevant to managing care of patient across entire stay
 - Real-time consolidated information
 - Efficient handover process
 - Improved discharge planning
 - Enterprise access to information
- Displaying resource requirements & potential constraints to inform management & planning
 - Align capacity & demand
 - Effective patient allocation

North .	Loc. A.	1 Asterdatal	PulciPris Spe	(D= 108	ted UC Review	5448	Appointment	Taska	Refe	rata i	bit feet 800	Texter Comment	in first	Due
Sam	1	Martinez, Robe	Private SU	ng Ing 1. 17	Dr.Swith 08 Juli 22102	860	PM 327944344		1445 (8.44 (8.55)		home 3 Dags	· · · · · · · · · · · · · · · · · · ·	2	0= 05:54
Cindy	2	Balley, Eugene	Public M		Dr Smith DR Aul 22002				ALL AND	-	CT Scan	Home If CT OK.	2.4	
Cindy	3	Ramirez, Earl	Prise 30/	Private	SURU	170	PM (1199) 141			oday	Cr Scan		91 3	-
Jenny	4	Murphy, Dorothy		Public	MED	Day			9000 001 	12.M 13.00 0	Family Mee		2	. 10
Janny		Green, Daris	48y	room	Genera	20	22-		1010 4010 PMS 047 007 0 Al 90.00 80.00 1010 1010 107	-1 Days		Awaiting hospice bed.	2	bei 03:0.
Sam		Pierce, r CO92175	62y	Private	GASTS Leroy,	Day 15	•		Auts 0007	14:00 Tomorrow		Nome if bloods normal.	-	od 00027
David	7	Mconiurphy, Dorothy		Private	GASTS	Day	Dr Jones 08 Jul		8.0 8.0 ne	23 Jul 10:00	Blood Res		0	
	ABOC.	GR C206411	29y		Taylor,	22	22:03		10.14 10.15 00.17	Tomorrow 23 Ad	Blood Res	Son will collect.		
David	•	Green, Doris	65y	Private	GASTS	Day 17	Dr Smith 08 Jul 22:03		All	09:00 Toslay			_	01:19
David	*	Pierce, Cheryl		Public	RESP	Day	Dr Tho., 08 Jul	e R hopey	0007 Red	22.Ad 0100 Ø			1 *	
Cindy	10	NHI C856116	79y	PUDDE	Proctor	22	22:03		MAN MAN	Tomorrow	Family Mee		3 1	- 52
Jenny	11	Grancov, Joan	497	Private	SURG	Day 15	Dr Tho 08 Jul		Bor Bor	10		Availing ACAT 22/2		2
Sam	12	Lave, -			SURG	Day	22:03 Dr Jones		047 Aut 0007		Aged Care		5 🏫	
David	13	Dean, Larry127101	40/	Private	Lomba	22	08 Jul 22:03				And Discourse	Partner will collect	04	
Cindy	14	Bowman, Harry IP	82v	Private	ORTH	Day 18					home Stars			
Janny	15	Sullivan, Ryan	-	Drivate	CARD						6 Days ph.u.i		0.4	




use only

Virtual Care: overview & positioning



What is Virtual Care?


- Long been recognised that patients recuperate better at home than in hospital
 - Also helps contain healthcare costs
- COVID accelerated digitally-enabled methods of care, demonstrating tech facilitates safer patient outcomes
- Virtual Care uses digital tech to monitor health data and transmit to providers for triage, assessment & care management
- Virtual care involves the patient in their care plan and gives them information and engagement in their care
- Gives patients better understanding of their condition, helping equip them to contribute to their recovery





Alcidion at the forefront of Virtual Care delivery...

- Alcidion originally developed Virtual Care for monitoring of COVID patients
 - Focused on visualisations so information was immediately meaningful to clinicians
 - Critical was our integration capability to source relevant data from hospital / diagnostic systems through to wearable devices allocated to patients
- Given flexibility & scalability of Miya Precision, we had ability to pivot quickly to assisting with COVID
 - Several customers impressed with our adaptability; highlights strong underlying foundations of platform



MIYA PRECISION




Case Study: Virtual Care at Sydney LHD

" rpaVirtual has now delivered virtual care safely with great results to over 63,000 patients.

Alcidion's Miya Platform provides our clinicians the tools they need to deliver great quality care virtually, with the best possible outcomes for patients."

> Miranda Shaw, General Manager, RPA Virtual Hospital





Virtual Care in action: product demonstration



Outlook

Key Comments

- Ending FY23 Q1 with strong contracted revenue of \$29.0M to be recognised in FY23, 69% higher than at same time last year
- Further \$2.6M of scheduled renewal, expected to be converted to contracted revenue over FY23
- Very confident in pipeline of opportunities, several of which are well progressed

Key Growth Drivers:

New Contract Wins


New contract wins build on long-term TCV while validating product offering

Contract Up-Sell

Adding new modules (services) to existing customers

Contract Renewals

Renewal of contracts at term end to continue recurring revenue streams



d to





Additional information with regard to Risk Management and Key Risks

There are various internal and external risks that may have a material impact on the Group's future financial performance and economic sustainability. The Group makes every

The Board takes a proactive approach to risk management. The Board has oversight of the Audit & Risk Committee, which is responsible for ensuring that risks, and opportunities, are identified in a timely manner and that the Group's objectives and activities are aligned with the risks and opportunities identified by the Board.

The Audit & Risk Committee meets at least 4 times a year to review the risk register and receive updates on and provides feedback to the Senior Leadership Team on the identification of risks and the progress/effectiveness of risk mitigation strategies.

Material risks that could adversely impact the Group's financial prospects along with mitigating actions taken by Alcidion are outlined below. These risks do not represent an exhaustive list of the risks Alcidion is exposed to, nor are they in order of significance.

Inability to attract and retain appropriately skilled employees results in skill shortages impacting business operations

Future financial and operational performance of the Group is significantly dependant on the performance and retention of key personnel. The unplanned or unexpected loss of key personnel, or the inability to attract and retain high performing individuals to the business may adversely impact the Group's ability to deliver on its customer commitments and its future financial performance.

Mitigating actions: Alcidion has introduced and developed initiatives to attract, develop and retain key people, including the implementation and constant review of an Employee Value Proposition (EVP) to remain an attractive employer; regular remuneration benchmarking; and collecting and responding to employees via an engagement platform. Alcidion allows time for graduates, interns and product engineers to focus on innovation. The company has mechanisms to allow open communication and visibility to the Senior Leadership Team to prioritise and consider innovative ideas.

Alcidion utilises multiple recruitment channels to attract the right employees and where appropriate uses staff augmentation services, to enhance and expand capabilities at short notice.



Additional information with regard to Risk Management and Key Risks (cont.)

Cyber security threat from Data breach, Targeted data theft and/or Operational disruption including Statutory Liability arising from Privacy and Data Breaches

A cyber security breach has the potential to disrupt the Group's information technology platform which is integral to the efficient operation of its business. A serious data breach could expose the business to statutory liability and reputational damage.

Mitigating actions: Alcidion has an ongoing Cyber security program of work in place. The Group maintains and regularly updates its suite of information technology security measures to restrict access to the Group's operating systems including multifactor authentication, firewalls, phishing identification software, offsite and cloud hosted solutions, and regular back up of data. The Group conducts regular penetration testing and training to educate its workforce and ensure its security measures remain at the forefront of available market solutions. Updated Privacy policies were released in 2022 in each of the jurisdictions we operate. The Group also maintains Cyber Enterprise Risk Management Insurance.

Dependence on third party IT suppliers and partners

Alcidion uses third party suppliers to support its products and operations and re-sells supports third party software solutions to enhance its product offering. There is a risk of these suppliers performing poorly or terminating their contracts with Alcidion which could adversely impact Alcidion's reputation and/or financial performance. There is no guarantee that the company will be able to find suitable industry partners that it can negotiate attractive commercial terms in the future.

Mitigating actions: Alcidion partners with reputable suppliers and performs Due Diligence on key partners. External agreements are reviewed and signed off by Legal Counsel. Significant contracts have minimum service level agreements written into them. Where possible multiple partners are used, providing a level of redundancy.

Failure to Deliver on contractual commitments with customer

Alcidion commits to programs of work with its customers, failure to deliver on this program in a timely fashion could lead to reputational damage, loss of contracts or Indemnities or damages payable in connection with key contracts

Mitigating actions: General Counsel reviews all customer contracts, and a risk analysis is performed on material bids. Alcidion has a rolling 12-month road map in place, which is made available to the product development, service delivery and sales teams. Changes to the roadmap are discussed with internal stakeholders and agreed prior to committing to changes. A Delegated Authority is in place to ensure the Board is comfortable with structural liabilities.



Disclaimer

The information contained in this document ("Document") has been prepared by Alcidion Group Limited ACN 143 142 410 (referred to as "Alcidion" or "Company"). This Document is current as at the date of this Document and should be read in conjunction with other Alcidion periodic and continuous disclosure announcements filed with the Australian Securities Exchange (ASX), available at www.asx.com.au.

The information in this Document is not intended to form the basis of any investment decision in relation to the Company or its assets and should not be considered as a recommendation to the Recipient to acquire securities in the Company. This Document is not a prospectus, profile statement or disclosure document and does not constitute an offer or invitation to acquire securities or otherwise invest in the Company, and no agreement to subscribe for securities will be entered into on the basis of this Document.

No representation or warranty, expressed or implied, is or will be made, and no responsibility or liability is or will be accepted by the Company, any of their respective officers, servants, agents or advisers (collectively "Limited Parties") as to or in relation to the accuracy, reasonableness, completeness or reliability of the information in this Document or any other written or oral information made available to any Recipients or their advisers. Any liability therefore is hereby expressly disclaimed. In particular, no representation or warranty is given as to the achievability or reasonableness of any future projections, management estimates or plans, prospects, returns or forecasts.

To the fullest extent permitted by law, the Limited Parties will not have any responsibility or liability for any loss or damage (whether foreseeable or not), however arising (including as a result of negligence), in relation to or in connection with the provision of this Document, the Recipient's or any other person's purported reliance on this Document, the failure to provide information of which any of the Limited Parties becomes aware or any errors in or omissions from this Document.

None of the Limited Parties makes or gives any representation, warranty or guarantee, express or implied, that the information in this Document is accurate, current, reliable or complete, has been or will be audited or independently verified, or that reasonable care has been taken in compiling, preparing or furnishing it. Various statements in this Document constitute statements relating to intentions, future acts and events including forecast financial information ("Forward Looking Statements"). Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that may cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed herein. The Limited Parties do not make or give any representation, warranty or guarantee, express or implied, that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable. No historical financial information, forecast financial information, estimates or projections contained in this Document or any other financial information derived from that information, can be relied upon as a promise or representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of achievement or reasonableness of any Forward Looking Statement, forecast financial information or other forecast.

The Limited Parties do not undertake any obligation to (and expressly disclaim any obligation to) provide the Recipients with access to any additional information or to correct any inaccuracies herein which may become apparent or to disseminate any updates or revisions to any Forward Looking Statements in this Document to reflect any change in expectations in relation to any such statements or any change in events, conditions or circumstances on which any such statement is based.

This document also contains statistics, data and other information relating to markets, market sizes, market shares, market positions and other industry data pertaining to the Alcidion's business and markets. Such information is generally based on independent market and industry data or research. The Alcidion has not independently verified, and cannot give any assurances as to the accuracy and completeness of the information sourced from market and industry data or research contained herein. Accordingly, the accuracy and completeness of such information is not guaranteed. There is no assurance that any of the forecasts or projections contained in the independent market and industry data or research will be achieved. Forecasts and projections involve risks and uncertainties and are subject to change based on various factors. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions.

Neither the receipt of this Document by any person nor any information contained in it or supplied with it or subsequently communicated to any person in connection with a proposed investment in the Company constitutes, or is to be taken as constituting, the giving of investment or financial product advice (or any other advice) to any such person. Each such person should make their own independent assessment of the merits or otherwise of investing in the Company and should seek their own professional advice in respect of any future investment opportunity and not act on the basis of any matter contained in this Document. In providing this Document, the Company has not considered the objectives, financial position, taxation situation or other needs of any particular Recipient.

The distribution of this document in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this document who are not in Australia, should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

Financial data

All financial amounts contained in this presentation are expressed in Australian dollars (unless otherwise stated). Any discrepancies between totals and sums of components in tables, figures and body content contained in this presentation are due to rounding. Tables, figures and body content contained in this presentation have not been amended by ALC to correct immaterial summation differences that may arise from this rounding convention.

Investors should also be aware that certain financial data included in this presentation including underlying NPAT and underlying EBIT/EBITDA and measures described as "pro-forma", are "non-IFRS financial information" under ASIC regulatory Guide 230 (disclosing non-IFRS financial information). The non-IFRS financial information financial measures do not have a standardised meaning prescribed by Australian International Reporting Standards (AIFRS) and, therefore, may not be comparable to similarly titled measures presented by other companies, nor should they be construed as an alternative to other measures determined in accordance with AIFRS. Investors are cautioned, therefore, not to place undue reliance on any non-IFRS financial measures included in this presentation.

For personal

